We have assembled an experienced team of executives with track records of success. Our leadership team is well versed in development, commercial, operational, and corporate functions—each crucial for long-term growth and well-being of a successful pharmaceutical business.

Pavan Cheruvu, MD

Chief Executive Officer

Dr. Cheruvu has served as the Chief Executive Officer of Axovant Sciences, Inc. since February 2018. Prior to joining Axovant, Dr. Cheruvu held roles of increasing responsibility at Roivant and supporting Axovant since 2015 and was appointed to the Roivant executive leadership team in 2017. A board-certified physician, Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training in a clinical fellowship in cardiovascular medicine at the University of California, San Francisco. Prior to his medical training, Dr. Cheruvu was a management consultant at McKinsey & Company, where he focused on biopharmaceutical strategy.

He earned his B.S.E. in biomedical engineering, B.S.E. in electrical engineering, and A.B. in chemistry from Duke University summa cum laude, his M.Sc. in computer science from Oxford University where he was a Rhodes Scholar, and his M.D. from Harvard Medical School.

Mark Altmeyer

President of Axovant Sciences GmbH &
Chief Commercial Officer

Mr. Altmeyer is President and Chief Commercial Officer of Axovant Sciences GmbH and joined our company in March 2015. He has 30 years of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a focus on therapies for central nervous system disorders. Previously, he served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led 1,700 employees and grew total revenues from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number-one selling drug in the United States in 2013. Earlier in his career, Mr. Altmeyer held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization, and Senior Vice President, Neuroscience Business Unit.

Mr. Altmeyer received an M.B.A. from Harvard Business School and a B.A. in economics from Middlebury College.

Gavin Corcoran, MD

Executive Vice President of Research & Development*
*Starting July 2018

Dr. Gavin Corcoran will be joining Axovant to serve as Executive Vice President of Research & Development. He has overseen successful drug development across multiple therapeutic areas including neurology and psychiatry. He currently serves as Chief Medical Officer at Allergan plc, and previously served as Chief Medical Officer of Actavis. Dr. Corcoran was Executive Vice President for Global Medicines Development at Forest Laboratories prior to the acquisition of Forest Laboratories by Actavis. In addition, Dr. Corcoran served as Head of Late Stage Clinical Development for Inflammation and Immunology at Celgene, and as Chief Scientific Officer and head of R&D at Stiefel Laboratories. Earlier in his career he held leadership roles in clinical development and regulatory affairs at Amgen, Schering-Plough, and Bayer. He received his MB BCh from the University of the Witwatersrand in South Africa and completed his clinical training in internal medicine and infectious diseases at the University of Texas Health Science Center at San Antonio.

Fraser Wright, PhD

Chief Technology Officer

Dr. Wright has joined Axovant to serve as Chief Technology Officer overseeing the company’s gene therapy initiatives. Dr. Wright is the Co-Founder and former Chief Technology Officer of Spark Therapeutics and has over 20 years of leadership experience in the development of novel vector-based biologic products. At Spark he oversaw process development and clinical-stage manufacturing for LUXTURNA™. Prior to Spark, he was the founding Scientific Director of the Clinical Vector Core Laboratory at The Children’s Hospital of Philadelphia, where he directed clinical core staff in gene therapy investigational product development, manufacture, and quality control testing for ten first-in-human viral vector investigational products including LUXTURNA™ and Kymriah®. He was also previously the Director of Development and Clinical Manufacturing at Avigen.

Dr. Wright was formerly a Research Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine, and he is the lead inventor on numerous issued patents during his time in that role. He received his BSc and PhD in biochemistry from the University of Toronto, where he was also an assistant professor of biochemistry and medicine.

Ilise Lombardo, MD

Senior Vice President, Clinical Research

Dr. Lombardo has served as Senior Vice President of Clinical Research at Axovant Sciences, Inc. since April 2015. She has 15 years of experience leading clinical development and medical affairs programs across multiple therapeutic areas including neurological and psychiatric disorders. She has successfully managed clinical development, regulatory authority approval, and post-marketing activities. Previously, she was Vice President, Clinical Development and Medical Affairs, at FORUM Pharmaceuticals. Earlier in her career, she led multitherapeutic groups and development teams at Pfizer. She is a trained psychiatrist and previously worked in academic research and clinical practice. Prior to entering the pharmaceutical industry, she was an Assistant Professor of Clinical Research at Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute.

Dr. Lombardo received an M.D. from Yale University, an M.Phil. from the University of Cambridge, and an A.B. in philosophy from Brown University. She completed a research fellowship in molecular biology at Yale University and the University of Cambridge, and completed her internship and residency in psychiatry as well as a four-year post-doctoral fellowship in molecular neuroimaging at Columbia University College of Physicians and Surgeons.

Gregory M. Weinhoff, MD

Chief Financial Officer

Dr. Weinhoff has served as Chief Financial Officer of Axovant Sciences, Inc. since August 2015. He has more than 20 years of experience in healthcare finance and operations, including as a venture capital investor, operating executive, and board member with Audit Committee experience. Previously, he was a partner at CHL Medical Partners, where he focused on investments in start-up and early-stage companies across therapeutics, diagnostics, medical devices and healthcare services. He was the founding Chief Executive Officer of Amicus Therapeutics and subsequently was a member of the Audit Committee of the company’s board of directors. Earlier in his career, he was founding President of VaxInnate and President of Resolvyx. He also held positions in the healthcare groups at J.H. Whitney & Co. and Morgan Stanley & Co.

Dr. Weinhoff received an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School (Baker Scholar), and an A.B. in economics from Harvard College.

Shankar Ramaswamy, MD

Senior Vice President, Business Development

Dr. Ramaswamy is Senior Vice President of Business Development at Axovant Sciences, Inc. and joined the company in March 2015. One of the earliest employees of Axovant, he has served the company in multiple roles including, most recently, Vice President of Global Medical Affairs.

Dr. Ramaswamy received an M.D. from Brown University and an A.B. in economics from Harvard University.

Michael Hayden, MD, PHD

Senior Scientific Advisor & Chairman of the Scientific Advisory Board

Dr. Michael Hayden has been appointed as a senior scientific advisor to the company and Chairman of Axovant’s newly established Scientific Advisory Board. Dr. Hayden is one of the world’s leading experts in the genetic basis of movement disorders and CNS drug development. He recently served as President of Global R&D and Chief Scientific Officer at Teva. Prior to Teva, he founded multiple biotechnology companies, including Aspreva Pharmaceuticals. He currently serves as Killam Professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine. Dr. Hayden played a key role in the discovery and development of GLYBERA®, the first approved gene therapy product in the Western world, and has received numerous awards including the Order of Canada, granted for his contributions to the understanding of Huntington’s disease and other genetic disorders. In 2008 he was named Canada’s Health Researcher of the Year and in 2017 he was inducted into the Canadian Medical Hall of Fame. Dr. Hayden received his MB ChB, PhD in Genetics, and DCH Diploma in Child Health from the University of Cape Town in South Africa. He completed his clinical training in internal medicine and clinical genetics at Harvard Medical School.